Joel Greenblatt Biotechnology

Gotham Asset Management, LLC

$16.1 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
EXEL Exelixis, Inc.	$12.1B	$37.3 Million 0.23% of portfolio	846,114	Q2 2025 Added 51.27%
UTHR United Therapeutics Corp	$13.7B	$25.7 Million 0.16% of portfolio	89,403	Q2 2025 Added 0.07%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$14.2 Million 0.09% of portfolio	27,005	Q2 2025 Reduced 15.73%
INCY Incyte Corp	$18.2B	$12.8 Million 0.08% of portfolio	187,825	Q2 2025 Added 65.44%
VRTX Vertex Pharmaceuticals Inc	$99.5B	$9.51 Million 0.06% of portfolio	21,356	Q2 2025 Reduced 23.12%
JAZZ Jazz Pharmaceuticals PLC	$7.1B	$7.27 Million 0.05% of portfolio	68,472	Q2 2025 Added 35.87%
BMRN Biomarin Pharmaceutical Inc	$10.6B	$6.57 Million 0.04% of portfolio	119,446	Q2 2025 Added 151.63%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$5.8 Million 0.04% of portfolio	17,787	Q2 2025 Added 22.53%
HALO Halozyme Therapeutics, Inc.	$8.95B	$3.54 Million 0.02% of portfolio	68,052	Q2 2025 Added 109.19%
CPRX Catalyst Pharmaceuticals, Inc.	$2.09B	$2.38 Million 0.01% of portfolio	109,725	Q2 2025 Added 131.93%
APLS Apellis Pharmaceuticals, Inc.	$2.63B	$2.06 Million 0.01% of portfolio	119,229	Q2 2025 Added 247.76%
PTGX Protagonist Therapeutics, Inc	$2.68B	$2.06 Million 0.01% of portfolio	37,287	Q2 2025 Added 61.61%
ADMA Adma Biologics, Inc.	$3.29B	$1.98 Million 0.01% of portfolio	108,993	Q2 2025 Reduced 33.64%
BCRX Biocryst Pharmaceuticals Inc	$1.55B	$1.81 Million 0.01% of portfolio	201,813	Q2 2025 Added 358.0%
PTCT Ptc Therapeutics, Inc.	$3.24B	$1.74 Million 0.01% of portfolio	35,629	Q2 2025 Added 642.27%
INVA Innoviva, Inc.	$1.4B	$1.7 Million 0.01% of portfolio	84,406	Q2 2025 Added 29.53%
TGTX Tg Therapeutics, Inc.	$3.94B	$1.63 Million 0.01% of portfolio	45,332	Q2 2025 Reduced 3.0%
CORT Corcept Therapeutics Inc	$7.88B	$1.27 Million 0.01% of portfolio	17,312	Q2 2025 Reduced 0.64%
HRMY Harmony Biosciences Holdings, Inc.	$2.1B	$1.25 Million 0.01% of portfolio	39,707	Q2 2025 Added 71.42%
MRNA Moderna, Inc.	$10B	$937,000 0.01% of portfolio	33,982	Q2 2025 New
VCYT Veracyte, Inc.	$2.06B	$890,000 0.01% of portfolio	32,939	Q2 2025 Added 74.46%
ADPT Adaptive Biotechnologies Corp	$1.81B	$837,000 0.01% of portfolio	71,887	Q2 2025 Added 572.28%
FOLD Amicus Therapeutics, Inc.	$1.96B	$782,000 0.0% of portfolio	136,536	Q2 2025 Added 152.89%
AUPH Aurinia Pharmaceuticals Inc.	$1.61B	$749,000 0.0% of portfolio	88,491	Q2 2025 Added 6.57%
ACLX Arcellx, Inc.	$3.19B	$648,000 0.0% of portfolio	9,842	Q2 2025 Reduced 5.84%
VCEL Vericel Corp	$1.72B	$581,000 0.0% of portfolio	13,659	Q2 2025 Added 0.04%
IONS Ionis Pharmaceuticals Inc	$5.85B	$564,000 0.0% of portfolio	14,279	Q2 2025 New
GANX Gain Therapeutics, Inc.	$18.2M	$442,000 0.0% of portfolio	245,896	Q2 2025 Added 59.69%
ROIV Roivant Sciences Ltd.	$8.15B	$441,000 0.0% of portfolio	39,149	Q2 2025 Added 0.31%
ACAD Acadia Pharmaceuticals Inc	$4.12B	$379,000 0.0% of portfolio	17,607	Q2 2025 Reduced 48.33%
SMMT Summit Therapeutics Inc.	$5.17B	$334,000 0.0% of portfolio	15,729	Q2 2025 Reduced 0.35%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$306,000 0.0% of portfolio	4,851	Q2 2025 Added 2.13%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$298,000 0.0% of portfolio	18,863	Q2 2025 New
MNKD Mannkind Corp	$942M	$266,000 0.0% of portfolio	71,189	Q2 2025 Added 6.69%
CRSP Crispr Therapeutics Ag	$4.42B	$248,000 0.0% of portfolio	5,101	Q2 2025 New
XERS Xeris Biopharma Holdings, Inc.	$992M	$153,000 0.0% of portfolio	32,766	Q2 2025 Added 101.86%
IMNM Immunome Inc.	$120M	$94,000 0.0% of portfolio	10,200	Q1 2025 New
AKBA Akebia Therapeutics, Inc.	$610M	$56,000 0.0% of portfolio	15,569	Q2 2025 New
GERN Geron Corp	$510M	$53,000 0.0% of portfolio	38,161	Q2 2025 New
IBRX Immunity Bio, Inc.	$989M	$42,000 0.0% of portfolio	16,224	Q2 2025 Reduced 63.95%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	27,256	Q2 2025 Added 109.19%

Shares Options

Joel Greenblatt

Joel Greenblatt is the founder and managing partner of Gotham Asset Management, a successful investment firm that focuses on value investing. Greenblatt is known for his expertise in value investing and his contrarian approach to investing. He has generated strong returns for his clients over the long term.

Track Joel Greenblatt's portfolio

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account